Benzinga Pro data, Helius Medical Tech (NASDAQ:HSDT) reported Q1 sales of $190.00 thousand. Earnings fell to a loss of $4.35 million, resulting in a 5.95% decrease from last quarter. In Q4, Helius Medical Tech brought in $258.00 thousand in sales but lost $4.10 million in earnings.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q1, Helius Medical Tech posted an ROCE of -0.61%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

For Helius Medical Tech, a negative ROCE ratio of -0.61% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Upcoming Earnings Estimate

Helius Medical Tech reported Q1 earnings per share at $-1.15/share, which did not meet analyst predictions of $-1.13/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.